The Priority Review

Category

Approvals

Decisions by the FDA and other regulators on new drugs, biologics and devices.

58 stories · page 5 of 5

Stories

  1. FDA approves Hovilpri for immunocompromised adults with unresponsive HSV lesions

    The FDA approved Hovilpri (pritelivir) tablets, its page current as of October 9, 2026, for immunocompromised adults whose herpes simplex lesions did not respond to acyclovir, valacyclovir or famciclovir. In a Phase 3 trial, all lesions healed by 28 days in 63% of patients on Hovilpri.

  2. FDA approves Hovilpri for immunocompromised patients with HSV lesions

    The FDA approved Hovilpri (pritelivir) tablets for adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus and have not responded to acyclovir, valacyclovir, or famciclovir. In a Phase 3 trial, 63% of patients treated with Hovilpri had all lesions healed by 28 days versus 34% with other medications.

  3. FDA approves tucatinib with trastuzumab and pertuzumab for HER2-positive breast cancer

    On October 7, 2026, the FDA approved Tukysa with trastuzumab and pertuzumab as maintenance treatment for HER2-positive breast cancer. The FDA said median progression-free survival was 24.9 months with tucatinib and 16.3 months with placebo.

  4. FDA approves atezolizumab plus chemotherapy for Stage III dMMR colon cancer

    The FDA approved atezolizumab with a fluoropyrimidine and oxaliplatin for Stage III mismatch repair deficient colon cancer, citing a disease-free survival hazard ratio of 0.50 in 711 adults and one pediatric patient. The approval covers adults and pediatric patients two years of age and older after complete resection.

  5. FDA approves atezolizumab with chemotherapy for Stage III dMMR colon cancer

    On October 8, 2026, the FDA approved atezolizumab (Tecentriq, Genentech, Inc.) with fluoropyrimidine and oxaliplatin for adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient colon cancer. The approval also covers atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for patients 12 years and older who weigh 40 kg or greater.

  6. FDA approves tucatinib with trastuzumab and pertuzumab for HER2-positive breast cancer maintenance

    On October 7, 2026, the FDA approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. The approval follows a randomized, double-blind, placebo-controlled trial of 654 patients that showed a median progression-free survival of 24.9 months versus 16.3 months in the placebo arm.

  7. FDA approves pirtobrutinib for previously untreated CLL or SLL

    The FDA approved pirtobrutinib (Jaypirca, Eli Lilly and Company) on October 2, 2026 for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion. The approval follows the BRUIN CLL-313 trial, which enrolled 282 patients and showed a median progression-free survival that was not estimable versus 33.5 months for bendamustine plus rituximab.

  8. FDA approves first pediatric heart valve built to be expanded as a child grows

    Edwards Lifesciences' Autus Size-Adjustable Valve is also the first valve approved in the U.S. with polymeric leaflets instead of animal tissue.

  9. FDA approves Emcitate, the first treatment for MCT8 deficiency

    Egetis Therapeutics' tiratricol treats the excess blood thyroid hormone of Allan-Herndon-Dudley syndrome. The company also received a rare pediatric disease priority review voucher.

  10. FDA approves Fayuvi, the first gene therapy for Sanfilippo syndrome type A

    Ultragenyx's one-time AAV9 infusion received standard full approval for children with MPS IIIA, and the company received a priority review voucher.